Benefits
DashboardNot registered yet? Get a free account.
Sign UpNot registered yet? Get a free account.
Sign Up
You're about to leave our website and go to an external link. Are you sure?
Tergene Biotech Limited, is an unlisted public company incorporated on 07 March, 2008. It is classified as a public limited company and is located in Rangareddi, Telangana. It's authorized share capital is INR 46.00 cr and the total paid-up capital is INR 44.95 cr.
Tergene Biotech Limited's operating revenue range is Under INR 1 cr for the financial year ending on 31 March, 2023.
Read more
Buy Dashboard using Credits
This action will use 1 of your credits. Are you sure you want to go ahead?
Credits Balance:
0
** All rupee values in INR lacs. Based on March 2023 numbers.
-100.0%
18.04%
-27.8%
135.35
-107.78
0.02
Buy Report or Plans
Company dashboard
Five year financials and ratios
Risk analysis
Interactive charts
All financials
All annual returns
MoA and AoA
Latest financials
Latest annual return
MoA and AoA
Five year financials and ratios
Shareholding and group structure
Litigation and more
Everything in financial report
Peers and financials
* GST not included
** Reports & MCA filings will be based on the latest available financials.
India
(1)
| State | Type | Address |
|---|
Locations on Map
Filter (4)
Severe Risk
Moderate Risk
Low Risk
Read more
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | |
|---|---|---|---|---|---|
| Sales | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Operating profit | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Net profit | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Gross margin | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Operating margin | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Net margin | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Networth | |||||
| Borrowings | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Assets | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Debt to equity | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Current ratio | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| ROE | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Days payable | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| WC days | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | |
|---|---|---|---|---|---|
| Equity Capital | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Reserves | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Borrowings + | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Long term borrowings | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Short term borrowings | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Trade payables + | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Days payable | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Other liabilities + | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Other non-current liabilities | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Other current liabilities | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Total liabilities | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Fixed Assets + | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Tangible assets | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| CWIP | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Intangible assets | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| LT loans and advances | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Other non-current assets | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Current assets + | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Inventories | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Trade receivables | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Cash and cash equivalents | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| ST loans and advances | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Other current assets | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Total assets | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | |
|---|---|---|---|---|---|
| Sales + | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Sales growth % | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Expenses + | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Cost of goods | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Employee cost | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Other costs | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Operating profit + | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Operating margin % | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Other income | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Interest | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Depreciation | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Exceptional items | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Profit before tax | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Tax | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Profit - disc. ops | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Net profit | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Net margin % | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | |
|---|---|---|---|---|---|
| Solvency + | |||||
| Total Debt/Equity | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Net Debt/Equity | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Total Debt/Assets | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Total Assets/Equity | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Liquidity + | |||||
| Current Ratio | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Quick Ratio | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Interest Coverage | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Performance | |||||
| Gross Margin | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Operating Margin | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Net Margin | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Return + | |||||
| Return on Equity | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Pre-tax ROCE | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Return on Assets | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Pre-tax ROIC | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Efficiency + | |||||
| Days Payable | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Days Inventory | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Days Receivable | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Fixed Asset Turnover | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Total Asset Turnover | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Working Capital | |||||
| Cash Conversion Cycle | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Working Capital Days | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Designation | Name | DIN/PAN | Tenure |
|---|---|---|---|
| Managing Director | Mosuvan Kuppusamy
Shareholder
|
00066698 | 17 years |
| Director | Sivakumaran Meenakshisunderam | 01284320 | 10 years |
| Whole-time Director | Sathyan Kuppusamy
Shareholder
|
01493015 | 17 years |
| Director | Santhanam Subramanian | 03516515 | 8 years |
| Director | Umesh Krishnamoorthy | 10195095 | 1 years |
| Kmp | Vijayudu Gajulapalli | <HIDDEN> | 1 years |
| CFO | Lonkari Sudhakar | <HIDDEN> | 3 years |
| Kmp | Kumar Janmejay | <HIDDEN> | 0 years |
| Name | Status | Paid up Capital | Common Directors | Address |
|---|---|---|---|---|
| TRIDENT LIFE SCIENCES LIMITED |
Amalgamated
|
1.6 L | 1 | Telangana |
| APL RESEARCH CENTRE LIMITED |
Amalgamated
|
12.3 Cr | 1 | Telangana |
| CUREPRO PARENTERALS LIMITED |
Amalgamated
|
13.3 Cr | 1 | Telangana |
| AUROZYMES LIMITED |
Amalgamated
|
5.0 L | 1 | Telangana |
| AUROACTIVE PHARMA PRIVATE LIMITED |
Active
|
100.0 Cr | 2 | Telangana |
| AURO PEPTIDES LIMITED |
Active
|
265.9 Cr | 1 | Telangana |
| AUROBINDO PHARMA FOUNDATION |
Active
|
1.0 L | 1 | Telangana |
| EUGIA STERILES PRIVATE LIMITED |
Active
|
44.2 Cr | 2 | Telangana |
| CURATEQ BIOLOGICS PRIVATE LIMITED |
Active
|
100.0 Cr | 1 | Telangana |
| APL HEALTHCARE LIMITED |
Active
|
216.0 Cr | 1 | Telangana |
| SAMIES TECHNOLOGIES PRIVATE LIMITED |
Active
|
1.5 L | 1 | Tamil Nadu |
| THERANYM BIOLOGICS PRIVATE LIMITED |
Active
|
10.0 L | 1 | Telangana |
| QULE PHARMA PRIVATE LIMITED |
Active
|
10.0 L | 1 | Andhra Pradesh |
| APITORIA PHARMA PRIVATE LIMITED |
Active
|
99.0 Cr | 1 | Telangana |
| EUGIA PHARMA SPECIALITIES LIMITED |
Active
|
621.0 Cr | 1 | Telangana |
| EUGIA SEZ PRIVATE LIMITED |
Active
|
4.0 Cr | 1 | Telangana |
| LYFIUS PHARMA PRIVATE LIMITED |
Active
|
10.0 L | 1 | Andhra Pradesh |
The incorporation date of TERGENE BIOTECH LIMITED is 07 March, 2008
The authorized share capital of TERGENE BIOTECH LIMITED is INR ₹ 46.0 Cr.
The paid-up capital of TERGENE BIOTECH LIMITED is INR ₹ 45.0 Cr.
The registered address of TERGENE BIOTECH LIMITED is Galaxy, Floors 22-24, Plot No. 1, Survey No. 83/1 Hyderaba d Knowledge City, Raidurg Panmak tha NA Hyderabad Rangareddi Telangana - 500032
The CIN number of TERGENE BIOTECH LIMITED is U24230TG2008PLC113178.
Expand
Delete
Collapse
See
details
